BellBrook Labs is dedicated to providing the pharmaceutical industry with enabling screening tools to accelerate the discovery of more effective therapies. As a small, R&D-driven company, we identify areas with a strong need but a significant technical hurdle, and then we develop a solution.

Transcreener® Biochemical Assay Technology: Our proprietary Transcreener® HTS Platform was designed to rapidly move new targets into HTS and streamline selectivity profiling within a target family. It relies on homogenous fluorescent immunodetection of nucleotides, including ADP, UDP, GDP, AMP, and GMP, formed by thousands of cellular enzymes. Among these are group transferase families, such as kinases and glycosyltransferases, that catalyze the covalent regulatory reactions central to cell signaling. Each Transcreener Assay provides a generic detection method for multiple enzyme families. This means you can focus on evaluating new therapeutic strategies and optimizing lead molecules rather than on time-consuming assay development for individual targets. Pharmaceutical and biotechnology screening labs have rapidly validated and adopted the platform worldwide.

🔗 http://bellbrooklabs.com

CONNECT:

Traci Pretsch, CFO
📧 traci.pretsch@bellbrooklabs.com
📞 608-227-4510
1232 Fourier Drive, Suite 115
Madison, Wisconsin 53717